Japan's PMDA Considering Data Monitoring Committee Guidance, Weighs In On Adaptive Design - DIA Japan
By
Pharmasia News / PharmAsia News Oct. 31, 2011 12:00 PM GMT
Japan / Word Count: 556 / Article # 28111031002
Executive Summary
TOKYO - Drug reviewers in Japan do not see as many adaptive trial designs as reviewers in the U.S., and to ensure data integrity for the potentially controversial trials companies should consult with the Pharmaceuticals and Medical Devices Agency as early as possible, an official said, while adding that regulatory guidance may soon be on the way
$35.00
Buy Now
For $35.00, purchase this 556-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.